The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Intermittent Porphyria Market Research Report 2024
Synopsis
Acute intermittent porphyria (AIP) is a genetic metabolic disorder affecting the production of heme, the oxygen-binding prosthetic group of hemoglobin. It is characterized by a deficiency of the enzyme porphobilinogen deaminase.
The global Acute Intermittent Porphyria market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Acute Intermittent Porphyria is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Acute Intermittent Porphyria is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Acute Intermittent Porphyria in Hospitals & Clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Acute Intermittent Porphyria include Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation and ACON Laboratories, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria.
Report Scope
The Acute Intermittent Porphyria market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Intermittent Porphyria market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Intermittent Porphyria companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dahaner
Roche
Bio-Rad Laboratories
Siemens
ARKRAY
Sysmex Corporation
ACON Laboratories
Segment by Type
Gonadotropin-Releasing Hormone Analogues
Prophylactic Hematin Infusions
Segment by Application
Hospitals & Clinics
Research Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Intermittent Porphyria companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acute intermittent porphyria (AIP) is a genetic metabolic disorder affecting the production of heme, the oxygen-binding prosthetic group of hemoglobin. It is characterized by a deficiency of the enzyme porphobilinogen deaminase.
The global Acute Intermittent Porphyria market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Acute Intermittent Porphyria is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Acute Intermittent Porphyria is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Acute Intermittent Porphyria in Hospitals & Clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Acute Intermittent Porphyria include Dahaner, Roche, Bio-Rad Laboratories, Siemens, ARKRAY, Sysmex Corporation and ACON Laboratories, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Acute Intermittent Porphyria, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Intermittent Porphyria.
Report Scope
The Acute Intermittent Porphyria market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Intermittent Porphyria market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Intermittent Porphyria companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Dahaner
Roche
Bio-Rad Laboratories
Siemens
ARKRAY
Sysmex Corporation
ACON Laboratories
Segment by Type
Gonadotropin-Releasing Hormone Analogues
Prophylactic Hematin Infusions
Segment by Application
Hospitals & Clinics
Research Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Intermittent Porphyria companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Intermittent Porphyria Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gonadotropin-Releasing Hormone Analogues
1.2.3 Prophylactic Hematin Infusions
1.3 Market by Application
1.3.1 Global Acute Intermittent Porphyria Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Clinics
1.3.3 Research Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Intermittent Porphyria Market Perspective (2019-2030)
2.2 Acute Intermittent Porphyria Growth Trends by Region
2.2.1 Global Acute Intermittent Porphyria Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acute Intermittent Porphyria Historic Market Size by Region (2019-2024)
2.2.3 Acute Intermittent Porphyria Forecasted Market Size by Region (2025-2030)
2.3 Acute Intermittent Porphyria Market Dynamics
2.3.1 Acute Intermittent Porphyria Industry Trends
2.3.2 Acute Intermittent Porphyria Market Drivers
2.3.3 Acute Intermittent Porphyria Market Challenges
2.3.4 Acute Intermittent Porphyria Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Intermittent Porphyria Players by Revenue
3.1.1 Global Top Acute Intermittent Porphyria Players by Revenue (2019-2024)
3.1.2 Global Acute Intermittent Porphyria Revenue Market Share by Players (2019-2024)
3.2 Global Acute Intermittent Porphyria Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Intermittent Porphyria Revenue
3.4 Global Acute Intermittent Porphyria Market Concentration Ratio
3.4.1 Global Acute Intermittent Porphyria Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Intermittent Porphyria Revenue in 2023
3.5 Acute Intermittent Porphyria Key Players Head office and Area Served
3.6 Key Players Acute Intermittent Porphyria Product Solution and Service
3.7 Date of Enter into Acute Intermittent Porphyria Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Intermittent Porphyria Breakdown Data by Type
4.1 Global Acute Intermittent Porphyria Historic Market Size by Type (2019-2024)
4.2 Global Acute Intermittent Porphyria Forecasted Market Size by Type (2025-2030)
5 Acute Intermittent Porphyria Breakdown Data by Application
5.1 Global Acute Intermittent Porphyria Historic Market Size by Application (2019-2024)
5.2 Global Acute Intermittent Porphyria Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acute Intermittent Porphyria Market Size (2019-2030)
6.2 North America Acute Intermittent Porphyria Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acute Intermittent Porphyria Market Size by Country (2019-2024)
6.4 North America Acute Intermittent Porphyria Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Intermittent Porphyria Market Size (2019-2030)
7.2 Europe Acute Intermittent Porphyria Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acute Intermittent Porphyria Market Size by Country (2019-2024)
7.4 Europe Acute Intermittent Porphyria Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Intermittent Porphyria Market Size (2019-2030)
8.2 Asia-Pacific Acute Intermittent Porphyria Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acute Intermittent Porphyria Market Size by Region (2019-2024)
8.4 Asia-Pacific Acute Intermittent Porphyria Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Intermittent Porphyria Market Size (2019-2030)
9.2 Latin America Acute Intermittent Porphyria Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acute Intermittent Porphyria Market Size by Country (2019-2024)
9.4 Latin America Acute Intermittent Porphyria Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Intermittent Porphyria Market Size (2019-2030)
10.2 Middle East & Africa Acute Intermittent Porphyria Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acute Intermittent Porphyria Market Size by Country (2019-2024)
10.4 Middle East & Africa Acute Intermittent Porphyria Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Dahaner
11.1.1 Dahaner Company Detail
11.1.2 Dahaner Business Overview
11.1.3 Dahaner Acute Intermittent Porphyria Introduction
11.1.4 Dahaner Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.1.5 Dahaner Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Acute Intermittent Porphyria Introduction
11.2.4 Roche Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Detail
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Acute Intermittent Porphyria Introduction
11.3.4 Bio-Rad Laboratories Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 Siemens
11.4.1 Siemens Company Detail
11.4.2 Siemens Business Overview
11.4.3 Siemens Acute Intermittent Porphyria Introduction
11.4.4 Siemens Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.4.5 Siemens Recent Development
11.5 ARKRAY
11.5.1 ARKRAY Company Detail
11.5.2 ARKRAY Business Overview
11.5.3 ARKRAY Acute Intermittent Porphyria Introduction
11.5.4 ARKRAY Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.5.5 ARKRAY Recent Development
11.6 Sysmex Corporation
11.6.1 Sysmex Corporation Company Detail
11.6.2 Sysmex Corporation Business Overview
11.6.3 Sysmex Corporation Acute Intermittent Porphyria Introduction
11.6.4 Sysmex Corporation Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.6.5 Sysmex Corporation Recent Development
11.7 ACON Laboratories
11.7.1 ACON Laboratories Company Detail
11.7.2 ACON Laboratories Business Overview
11.7.3 ACON Laboratories Acute Intermittent Porphyria Introduction
11.7.4 ACON Laboratories Revenue in Acute Intermittent Porphyria Business (2019-2024)
11.7.5 ACON Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
